)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Theravance Biopharma
Theravance Biopharma (TBPH) investor relations material
Theravance Biopharma has been acquired by Zymeworks Inc
Theravance Biopharma Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary25 Aug, 2026
Executive summary
A definitive proxy statement was filed regarding a proposed transaction with Zymeworks Inc., urging shareholders to review all related materials for important information.
The company presented results from the Phase 3 CYPRESS Study of ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA), including post hoc analyses and regulatory updates.
Forward-looking statements highlight risks and uncertainties, including shareholder approval, regulatory outcomes, and potential litigation related to the proposed transaction.
Voting matters and shareholder proposals
Shareholders are being solicited to vote on the proposed transaction with Zymeworks Inc., with details provided in the definitive proxy statement.
The interests of directors, executive officers, and certain employees in the transaction may differ from those of shareholders generally.
Executive compensation and say-on-pay
Information regarding the direct and indirect interests of directors and executive officers in the proposed transaction is available in the proxy statement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Theravance Biopharma
- Shareholders to vote on $17.00 per share cash merger with Zymeworks and contingent value rights.TBPH
Proxy filing - Merger approval sought: $17/share cash plus CVR; board recommends, closing expected H2 2026.TBPHProxy filing
- Definitive merger with Zymeworks, 11% revenue growth, and major cost reductions in Q2 2026.TBPHQ2 2026
- Profitable COPD drug funds late-stage rare disease asset, with global launch plans and strong IP.TBPH7th Annual Evercore ISI HealthCONx Conference
- Merger agreement provides $17/share cash plus CVR for 80% of future ampreloxetine proceeds.TBPHProxy filing
- YUPELRI revenue up 15% YoY, net loss narrows, and restructuring targets major cost savings.TBPHQ1 2026
- Ampreloxetine targets a critical gap in MSA-related nOH, with pivotal data expected Q1 2026.TBPHKOL Event
- YUPELRI and TRELEGY sales rose, cash remains strong, and ampreloxetine advances in Phase 3.TBPHQ1 2025
- Record sales, milestone payments, and pipeline progress support growth and strategic options.TBPHQ4 2024
Theravance Biopharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Theravance Biopharma Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of respiratory and organ-selective medicines. The company's primary product is YUPELRI (revefenacin), a once-daily nebulized therapy used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Theravance Biopharma is also involved in the development of Ampreloxetine, an investigational norepinephrine reuptake inhibitor, targeting neurogenic orthostatic hypotension, and has collaborations for additional research in respiratory and immunological disorders. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.